is tirzepatide a glp 1 agonist Tirzepatide, dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Tirzepatide vs Semaglutide for Weight
Description
Weight Loss Varied Widely Among Patients About half of all participants (50.1%) stopped GLP-1-based treatment within one year, defined as a gap of at least 60 days without medication
[Google Scholar] [22].Yang XD, Yang YY
10.3389/fcdhc.2023.1293926 23
doi: 10.1001/jamaoto.2024.4852 [DOI] [PMC free article] [PubMed] [Google Scholar] 32
However, the duration of treatment in those studies is typically short, the quality of the patient follow-up is questionable, and evidence that prescriptions were actually taken is absent
